Anti-nephrin antibodies in people with idiopathic nephrotic syndrome
Official title: Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Run by Mario Negri Institute for Pharmacological Research · NCT06334692 · Data updated 2026-11-12
This project tests whether adults with idiopathic nephrotic syndrome (including MCD, FSGS, and post-transplant FSGS relapse) have circulating anti-nephrin autoantibodies compared with people with primary membranous nephropathy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Mario Negri Institute for Pharmacological Research Academic / other |
| Locations | 1 site (Ranica, BG) |
| Status | Recruiting |
| Started | March 19, 2024 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | September 4, 2025 |
| Trial ID | NCT06334692 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with biopsy-proven idiopathic MCD or FSGS (including post-transplant recurrence) or adults with biopsy-proven primary membranous nephropathy who consent to sample storage in the certified biobank are ideal candidates.
✕Probably not a fit
Patients under 18, those with a plausible secondary cause of nephrotic syndrome or active viral/bacterial infection at the time of blood collection are not expected to benefit from participation in this retrospective analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, case-control analysis measuring circulating anti-nephrin autoantibodies by in-house ELISA and commercial ELISA kits (DBA Italy / Abbexa) using samples stored in a certified biobank. Cases are adults with biopsy-proven idiopathic minimal change disease or focal segmental glomerulosclerosis, including those with post-transplant recurrence, and controls are adults with biopsy-proven primary membranous nephropathy. Patients with possible secondary causes of nephrotic syndrome or active infections at the time of sampling are excluded. The main outcome is the presence and level of anti-nephrin antibodies in cases versus controls to explore a possible biomarker linked to disease and recurrence.
Why it matters
Potential benefit: If confirmed, detecting anti-nephrin antibodies could provide a blood biomarker to help diagnose disease subtype and identify patients at higher risk of recurrence after transplant.
How similar studies have gone: Early published reports have identified anti-nephrin autoantibodies in subsets of MCD/FSGS patients, but the evidence is still emerging and requires independent validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (\>18 years) males and females * Patients with biopsy-proven idiopathic MCD or FSGS (cases) * Patients with biopsy-proven idiopathic membranous nephropathy (controls) * Patients who provided consent to store their samples in the certified CRB biobank Exclusion Criteria: * Reasonable possibility of a secondary cause of NS (for cases) or MN (for controls) at time of blood collections * Active viral or bacterial infections at time of blood collections
Where it's running
-
Clinical Research Center for Rare Disease Aldo e Cele Daccò
Ranica, Bg, Italy Recruiting
Study contacts
- Study coordinator: Federica Casiraghi, PhD
- Email: federica.casiraghi@marionegri.it
- Phone: +3903545351
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
-
SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome
This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.
-
Atacicept for multiple autoimmune glomerular diseases
This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.
-
Multitarget approach for primary podocytopathies
This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.
-
Follow-up on Rituximab treatment for children's nephrotic syndrome
This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.
-
Investigating the role of a protein in kidney damage related to nephrotic syndrome
This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.